Probiomed has been acquired by Sanfer
The shareholders of Probiomed S.A. de C.V. have sold the company to Laboratorios Sanfer.
Probiomed was founded in 1970 and is a vertically integrated developer, manufacturer and marketer of pharmaceutical and biopharmaceutical products. The company has three production plants and one of the most advanced R&D platforms in the region. The R&D team has 46 engineers who have developed and launched over 120 products, 14 of which were biopharmaceuticals.
Sanfer, with over 80 years of history, is one of the leading companies in the Mexican pharmaceutical market. It participates in more than 10 therapeutic areas, including infectiology, algology, cardiology, gastroenterology, central nervous system, metabolic syndrome, gynecology, urology, oncology, over-the-counter products and animal health products for all types of species.
Oaklins’ team in Mexico acted as the financial advisor to Probiomed in the debt restructuring of US$120 million under Chapter 11 “Concurso Mercantil” in Mexico, as well as in the structuring of the acquisition by Sanfer, resulting in an equity injection of US$30 million.
Talk to the deal team
Related deals
Yxion has been acquired by Normec
Normec has acquired Dutch consultancy Yxion from Antea. Through this acquisition, Normec continues its acquisition strategy in Europe, while also looking for expansion opportunities in the United States.
Learn moreAMC Media Group has been acquired by Formedics
AMC Media Group, a healthcare professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician’s Weekly and OncWeekly.
Learn moreLuxid Group has sold a minority stake to Voland Partners
Finnish marketing technology pioneer Luxid Group has sold its minority stake to the private equity company Voland Partners to boost its international growth.
Learn more